Aktiesnakken — Juni 2010
-
de testede zalut ikke mod best supportive care men mod et aktivt stof!
-
sindssygt
-
jeg kan ikke høre spørgsmålene
-
de regner stadig med at sælge i h2 og regner på at få prisen
-
kursen er 57,70-95 hvis det er det
-
cash is important to the company
-
han nævnte shareholders interesse (åh jan)
-
super godt!
-
vi tager den senere rth
-
ikke sådan endnu... men se aka's live referat på IR-live som jcbn skriver.
-
Arzerra er helt unik
-
og outperformer alle andre cd20 stoffer i klinikken
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind